HESI LPN
HESI Practice Test Pharmacology Questions
Question 1 of 5
A client with diabetes mellitus type 2 is prescribed sitagliptin. The nurse should monitor for which potential adverse effect?
Correct Answer: A
Rationale: Corrected
Rationale: Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor used in type 2 diabetes, has been associated with rare cases of pancreatitis.
Therefore, the nurse should monitor for signs and symptoms of pancreatitis such as severe abdominal pain, nausea, and vomiting. While hypoglycemia is a potential adverse effect of some diabetes medications, it is less common with sitagliptin. Hyperglycemia is the condition being treated and is not an expected adverse effect of sitagliptin.
Question 2 of 5
A client with bipolar disorder is taking lithium. Which client assessment data would indicate a potential adverse effect of lithium therapy?
Correct Answer: B
Rationale: When assessing a client taking lithium, dry mouth and increased thirst are indicators of potential adverse effects. Lithium can lead to nephrogenic diabetes insipidus, causing polyuria and subsequent increased thirst due to impaired water reabsorption in the kidneys. Tremors can also be a sign of lithium toxicity. Monitoring and recognizing these symptoms are crucial in managing lithium therapy and preventing further complications.
Question 3 of 5
A client with diabetes mellitus is prescribed insulin glargine. What information should the practical nurse (PN) provide to the client about this medication?
Correct Answer: B
Rationale: Insulin glargine is a long-acting insulin that should not be mixed with other insulins in the same syringe. Mixing it with other insulins can alter its pharmacokinetics and effectiveness. Insulin glargine is usually administered at the same time each day, often at bedtime, to provide a consistent basal level of insulin over 24 hours.
Question 4 of 5
A client with a diagnosis of bipolar disorder is prescribed lamotrigine. The nurse should monitor for which potential adverse effect?
Correct Answer: A
Rationale: Failed to generate a rationale of 500+ characters after 5 retries.
Question 5 of 5
A client diagnosed with multiple sclerosis self-administers beta-1 interferon subcutaneously
Correct Answer: D
Rationale: Encouraging the client to continue taking the medication is crucial in the management of multiple sclerosis. Beta-1 interferon is a disease-modifying drug used to reduce the frequency and severity of relapses in multiple sclerosis. Discontinuing the medication without medical advice can lead to disease exacerbation. It is essential for the client to maintain regular dosing to achieve optimal therapeutic effects and disease control.